The volume of biopharmaceutical deals have steadily declined each quarter this year, with only 200 recorded in the third quarter, a 23 percent fall over the second-quarter deal total and a 28 percent drop over the first-quarter number. However, in terms of value, third-quarter deals represented a total value of $21.7 billion, in line with the first quarter, and double that generated in the second quarter. (See Biopharma Deals: 2017, page 2.) Read More
The use of artificial intelligence (AI) in drug development has increased substantially over the last few years. And both large pharmaceutical companies and venture capital are starting to take notice. Read More
